Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Raises $35M in Series D Fundraising

NEW YORK (GenomeWeb) ­– Atlas Genetics announced today that it has completed a $35 million Series D financing round.

All of Atlas' Series C round investors — who contributed $20 million in January 2015 — participated in the Series D round. These include Novartis Venture Funds, Consort Medical, Johnson & Johnson Innovation - JJDC, Inc, Life Science Partners, BB Biotech Ventures, RMI Partners, and Technology Venture Partners.

The company also had one new investor — Chinese in vitro diagnostic assay developer Wondfo Biotech, based in Guangzhou, Guangdong Province.

Atlas announced that it had received CE marking on its rapid point-of-care io molecular diagnostic system and Chlamydia trachomatis assay last year. The new funding will now finance clinical trials and commercial launch of a combined test for chlamydia and gonorrhea, the company said, adding that it intends to seek regulatory approvals in the US for the CT/NG test near the end of 2017.

Part of the funding will also be applied toward menu expansion for the io system as well as increasing cartridge manufacturing capacity.

"We believe that Atlas Genetics is poised to become a world leader in POC molecular diagnostics and we plan to roll out new assays in a range of clinical areas over the next two years and beyond," Atlas CEO John Clarkson said in a statement.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.